United Kingdom· GB-APID-34349311000001108
Keytruda 100mg/4ml concentrate for solution for infusion vials
A pembrolizumab product containing pembrolizumab, registered in United Kingdom by Merck Sharp & Dohme (UK) Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Pembrolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FF02 (pembrolizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Pembrolizumab · ATC L01FF02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pembrolizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pembrolizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$245.95
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Pembrolizumab
- Manufacturer
- Merck Sharp & Dohme (UK) Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FF02
- ATC class
- Pembrolizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 7
- gtin5013945301878
- gtin5013945304022
- gtin00191778008968
- gtin00191778019551
- gtin00191778024326
- gtin0191778025422
- gtin00191778025422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for pembrolizumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pembrolizumab · interactions on record
20 records
- 3 severe
- 17 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pembrolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainKEYTRUDA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandKeytrudaMerck Sharp & Dohme B.V.
- BelgiumKeytruda 25 mg/mlMerck Sharp & Dohme
- CzechiaKEYTRUDAMerck Sharp & Dohme B.V., Haarlem
- IrelandKEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV,
- SwedenKEYTRUDA 25 mg/ml Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
- PolandKeytrudaMerck Sharp & Dohme B.V.
- SwitzerlandKeytruda
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Keytruda
- Liechtenstein · Keytruda
- Norway · Keytruda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5b323186-e6d7-4770-99ca-eee927ea2ee8 GET /v1/drugs/5b323186-e6d7-4770-99ca-eee927ea2ee8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "34349311000001108",
"desc": "Keytruda 100mg/4ml concentrate for solution for infusion vials (Merck Sharp & Dohme (UK) Ltd)",
"form": "Solution for infusion",
"vpid": "34378411000001105",
"source": "dmd",
"vtm_id": "777104007",
"strength": "25 mg",
"substance": "Pembrolizumab",
"ingredient": "Pembrolizumab",
"supplier_code": "39306911000001106"
}See everything about pembrolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.